Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURN-COVID Biobank
NL-OMON60149Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Amsterdam University Medical Center. Primary endpoints: SARS-CoV-2 viral load kinetics and occurrence of infection during prophylaxis, Viral variants, spike mutations, and immune escape and 2 more. Started Nov 2024; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON60149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60149.